PepGen to discontinue development of experimental Duchenne therapy; shares drop

PepGen (PEPG.O) announced it will halt development of its Duchenne muscular dystrophy (DMD) therapy, PGN-EDO51, after a mid-stage study failed to achieve target levels of dystrophin production, a key protein lacking in DMD patients; consequently, shares fell 9.5% to $1.43 in extended trading. The company will now shift its focus to a myotonic dystrophy therapy, with early-stage data expected in the second half of the year and mid-stage data in Q1 2026, and wind down all DMD-related R&D.

Analysis

PepGen (PEPG.O) has announced the discontinuation of its Duchenne muscular dystrophy (DMD) therapy, PGN-EDO51, following a mid-stage clinical trial where the drug failed to achieve target levels of dystrophin production, a crucial protein absent in DMD patients. This negative development led to an immediate 9.5% drop in PepGen's shares to $1.43 in extended trading, consistent with the strongly negative sentiment signal (per-ticker sentiment for PEPG: -0.85). The decision to halt the DMD program, a condition affecting an estimated one in 3,500 male births worldwide, marks a significant strategic shift for the company. PepGen will now wind down all DMD-related research and development and redirect its focus and resources towards a therapeutic candidate for myotonic dystrophy, another muscle wasting disorder. Key upcoming catalysts for this new lead program include early-stage study data anticipated in the second half of 2024, followed by mid-stage study data expected in the first quarter of 2026, which will be critical determinants of the company's future valuation.

Key Decisions for Investors

• The discontinuation of PepGen's PGN-EDO51 Duchenne muscular dystrophy program, following its failure in a mid-stage study and resulting in a 9.5% share price decline to $1.43, necessitates a re-evaluation of the company's risk profile and pipeline valuation.
• Investors should now focus on the company's strategic pivot to its myotonic dystrophy therapy, with key catalysts being early-stage data expected in the second half of 2024 and mid-stage results in the first quarter of 2026.
• Carefully monitor the progress and upcoming data from the myotonic dystrophy program, as its success is now paramount to PepGen’s future and any potential stock recovery, acknowledging the inherent risks of early-stage drug development.